Meeting
2016 Genitourinary Cancers Symposium
Phosphodiesterase type 5 inhibitors (PDE5i) and prostate cancer recurrence.
Authors
Stacy Loeb
New York University Langone Medical Center, New York City, NY
Stacy Loeb , Yasin Folkvaljon , David Robinson , Thorsten Schlomm , Hans Garmo , Pär Stattin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 55)
DOI
10.1200/jco.2016.34.2_suppl.55
Abstract #
55
Poster Bd #
C15
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Validation of GEMCaP as a DNA based biomarker to predict disease recurrence in patients undergoing prostatectomy for prostate cancer.
First Author: Hao Gia Nguyen
Poster
2023 ASCO Genitourinary Cancers Symposium
A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.
First Author: Karan Jatwani
Poster
2023 ASCO Genitourinary Cancers Symposium
Prediction of early prostate cancer recurrence using a liquid biopsy approach.
First Author: Kambiz Rahbar
Poster
2022 ASCO Genitourinary Cancers Symposium
Salvage radiotherapy (SRT) in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer.
First Author: Markus Grabbert